Oppenheimer analyst Hartaj Singh maintained a Buy rating on United Therapeutics (NASDAQ:UTHR) Corp. on Wednesday, setting a price target of $275, which is approximately 66.19% above the present share price of $165.47.
Singh expects United Therapeutics Corp . to post earnings per share (EPS) of $2.22 for the first quarter of 2021.
The current consensus among 7 TipRanks analysts is for a Strong Buy rating of shares in United Therapeutics, with an average price target of $218.29.
The analysts price targets range from a high of $275 to a low of $195.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $384.9 million and a net profit of $65.3 million. The company's market cap is $7.37 billion.
According to TipRanks.com, Oppenheimer analyst Hartaj Singh is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 13.2% and a 46.22% success rate.
United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.